A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
Authors:
- Michelle A. RudekMRMichelle A. Rudek
- Ping HePHPing He
- Frank-Thorsten HafnerFHFrank-Thorsten Hafner
- Martin RadtkeMRMartin Radtke
- John J. WrightJWJohn J. Wright
- B. Douglas SmithBSB. Douglas Smith
- Wells A. MessersmithWMWells A. Messersmith
- Manuel HidalgoMHManuel Hidalgo
- Sharyn D. BakerSBSharyn D. Baker
- 1 February 2007
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 846 (1-2) , 1-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- Raf Kinase Inhibitors in OncologyOncology Research and Treatment, 2005
- Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumorsInt. Journal of Clinical Pharmacology and Therapeutics, 2002
- The Ras-Raf-MEK-ERK Pathway in the Treatment of CancerOncology Research and Treatment, 2002
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid MalignanciesCurrent Pharmaceutical Design, 2002
- BAY 43-9006: Preclinical DataCurrent Pharmaceutical Design, 2002
- Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactionsBiochemical Journal, 2000
- MAP kinase pathwaysProgress in Biophysics and Molecular Biology, 1999
- VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine KinasesBiochemical and Biophysical Research Communications, 1999